On the design of national vaccination programmes

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3143-3145

  van der Zeijst, B A M ^a   Dijkman, M I ^a   Luytjes, W ^a   van Alphen, A J W ^a   van den Dobbelsteen, G P J M ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Correlates of protection; Immunisation programme; Vaccination schedule

Indexed keywords

HAEMOPHILUS INFLUENZAE VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE;

ADAPTATION; ARTICLE; BORDETELLA PERTUSSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; IMMUNIZATION; MENINGOCOCCOSIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 33947575319     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.076     Document Type: Article

References (13)

1. Kimman T.G., Boot H.J., Berbers G.A.M., Vermeer-de Bondt P.E., de Wit G.A., and de Melker H.E. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine 24 (2006) 4769-4778
2. Erickson L.J., De Wals P., and Farand L. An analytical framework for immunization programs in Canada. Vaccine 23 (2005) 2470-2476
3. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20 (2001) 63-75
4. Lambert P.H., Liu M., and Siegrist C.A. Can successful vaccines teach us how to induce efficient protective immune responses?. Nat Med 11 (2005) S54-S62
5. Trotter G.L., and Edmunds W.J. Reassessing the cost-effectiveness of menigococcal serogroup C conjugate (MCC) Vaccines using a transmission dynamic model. Med Decis Making 26 (2006) 38-47
6. Trotter C.L., Edmunds W.J., Ramsay M.E., and Miller E. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Human Vaccines 2 (2006) 468-473
7. Johnson N.G., Ruggeberg J.U., Balfour G.F., Chen Lee Y., Liddy H., Irving D., et al. Haemophilus influenza type b reemergence after combination immunization. Emerg Infect Dis 12 (2006) 937-941
8. Heath P.T., Booy R., Azzopardi H.J., Slack M.P.E., Bowen-Morris J., Griffiths H., et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 284 (2000) 2334-2340
9. Withney C.G., Pilishvili T., Farley M.M., Shaffner W., Graig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 (2006) 1495-1502
10. Healy C.M., and Baker C.J. Prospects for prevention of childhood infections by maternal immunization. Curr Opin Infect Dis 19 (2006) 271-276
11. Patten S., Robinson Vollman A., Manning S.D., Mucenski M., Vidakovich J., and Davies H.D. Vaccination for Group B Streptococcus during pregnancy: attitudes and concerns of women and health care providers. Soc Sci Med 63 (2006) 47-58
12. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. Plos Pathogens 2 (2006) 662-670
13. Roduit C., Bozzotti P., Mielcarek N., Lambert P.H., del Giudice G., Locht C., et al. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a Murine Model: evidence for early control of pertussis. Infect Immun 70 (2002) 3521-3528